Barriers and facilitators to prescribing medicinal cannabis in New Zealand.

Simple item page
dc.citation.issue2
dc.citation.volume15
dc.contributor.authorWithanarachchie V
dc.contributor.authorRychert M
dc.contributor.authorWilkins C
dc.contributor.editorGoodyear-Smith F
dc.coverage.spatialAustralia
dc.date.accessioned2024-07-01T02:46:28Z
dc.date.available2024-07-01T02:46:28Z
dc.date.issued2023-03-02
dc.description.abstractIntroduction: The New Zealand Medicinal Cannabis Scheme (NZMCS) was established in April 2020 with the aim of expanding access to quality controlled medicinal cannabis products and developing a domestic medicinal cannabis industry. Yet, two years later, many patients report challenges in utilising the NZMCS, including physicians’ reluctance to provide prescriptions for products. Aim: To explore the barriers and facilitators to prescribing medicinal cannabis in New Zealand. Methods: We conducted semi-structured interviews with 31 New Zealand physicians (general practitioners, specialists, and cannabis clinicians) who had discussed medicinal cannabis with patients in the last 6 months. Results: Physicians reported the principal barrier to prescribing medicinal cannabis was the limited clinical evidence to support cannabis therapy. Further barriers included: a perceived lack of knowledge of medicinal cannabis; concerns over professional reputation; social stigma; and the price of products. Conversely, the factors that facilitated cannabis prescribing included patients’ and physicians’ knowledge of medicinal cannabis; some physicians’ desire to avoid patients having to engage with private cannabis clinics; and the timing of prescription requests (ie considering medicinal cannabis after other treatments had been exhausted). Discussion: Further clinical research of medicinal cannabis medications, education and training, and information would support physicians to deliver more informed advice to patients and enhance professional confidence with cannabis therapies.
dc.description.confidentialfalse
dc.format.pagination135-146
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37390030
dc.identifier.citationWithanarachchie V, Rychert M, Wilkins C. (2023). Barriers and facilitators to prescribing medicinal cannabis in New Zealand.. J Prim Health Care. 15. 2. (pp. 135-146).
dc.identifier.doi10.1071/HC22122
dc.identifier.eissn1172-6156
dc.identifier.elements-typejournal-article
dc.identifier.issn1172-6164
dc.identifier.piiHC22122
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/70050
dc.languageeng
dc.publisherCSIRO Publishing on behalf of The Royal New Zealand College of General Practitioners
dc.publisher.urihttps://www.publish.csiro.au/HC/HC22122
dc.relation.isPartOfJ Prim Health Care
dc.rights(c) 2023 The Author/s
dc.rightsCC BY-NC-ND 4.0
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHumans
dc.subjectMedical Marijuana
dc.subjectNew Zealand
dc.subjectGeneral Practitioners
dc.subjectEmotions
dc.subjectKnowledge
dc.titleBarriers and facilitators to prescribing medicinal cannabis in New Zealand.
dc.typeJournal article
pubs.elements-id477932
pubs.organisational-groupCollege of Health
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Published version.pdf
Size:
791.05 KB
Format:
Adobe Portable Document Format
Description:
477932 PDF.pdf
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles